Starling Oncology, Inc. Common Stock (STLN) is a publicly traded the market company. As of October 1, 2026, STLN trades at $6.28 with a market cap of $644.11M and a P/E ratio of 0.00. STLN moved -1.58% today. Year to date, STLN is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $4.85 to $7.13. Analyst consensus is strong buy with an average price target of $9.25. Rallies surfaces STLN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Starling Oncology highlights leadership participation at Deutsche Bank 2026 Healthcare Summit: Starling Oncology said Chief Clinical Officer Jeffrey Langsam joined a “Future of Oncology” panel at Deutsche Bank’s 2026 Healthcare Summit on Sept. 17. Chief Medical Officer Yale D. Podnos spoke at the PCOC conference on Sept. 25 and is scheduled to speak at two more oncology events in October and November.
| Metric | Value |
|---|---|
| Price | $6.28 |
| Market Cap | $644.11M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.13 |
| 52-Week Low | $4.85 |
| Volume | 843.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover STLN: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.25.